Drug Profile


Alternative Names: CIM331; IL-31RA monoclonal antibody - Chugai

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Class Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 31 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Pruritus

Most Recent Events

  • 02 Mar 2017 Interim efficacy and adverse events data from the XCIMA phase II trial in Atopic dermatitis released by Chugai Biopharmaceuticals
  • 28 Sep 2016 Nemolizumab licensed to Maruho for Atopic dermatitis and Pruritus in Japan
  • 20 Jul 2016 Galderma enters into a global licensing agreement with Chugai for development and marketing of nemolizumab
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top